News Update on Cell Transplantation Research: April – 2019

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Oral Brincidofovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation

Cytomegalovirus (CMV) infection could be a common complication of allogeneic haematogenic cell transplantation (HCT). during this trial, we have a tendency to randomised adult herpes-seropositive HCT recipients while not CMV pathology at screening 2:1 to receive brincidofovir or placebo till week fourteen post-HCT. organisation was stratified by center and risk of herpes infection. Patients were assessed weekly through week fifteen and each third week thenceforth through week twenty four post-HCT. Patients UN agency developed clinically important herpes infection (CS-CMVi; CMV pathology requiring preventative medical aid or CMV disease) discontinued  the study drug and started anti-CMV treatment. the first terminus was the proportion of patients with CS-CMVi through week twenty four post-HCT; patients UN agency discontinued  the trial or with missing information were imputed as primary endpoint events. Between August 2013 and June 2015, 452 patients were randomised at a median of fifteen days when HCT and received study drug. The proportion of patients UN agency developed CS-CMVi or were imputed as having a primary terminus event through week twenty four was similar between brincidofovir-treated patients and placebo recipients (155 of 303 [51.2%] versus seventy eight of 149 [52.3%]; odds quantitative relation, .95 [95% confidence interval, .64 to 1.41]; P = .805); fewer brincidofovir recipients developed herpes pathology through week fourteen compared with placebo recipients (41.6%; P < .001). Serious adverse events were additional frequent among brincidofovir recipients (57.1% versus thirty seven.6%), driven by acute graft-versus-host unwellness (32.3% versus half-dozen.0%) and diarrhoea (6.9% versus a pair of.7%). Week twenty four all-cause mortality was fifteen.5% among brincidofovir recipients and ten.1% among placebo recipients. Brincidofovir didn’t cut back CS-CMVi by week twenty four post-HCT and was related to gi toxicity. [1]

Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial


Maintenance medical aid following autologous vegetative cell transplantation (ASCT) will delay malady progression and prolong survival in patients with myeloma. Ixazomib is ideally fitted to maintenance medical aid given its convenient once-weekly oral dosing and low toxicity profile. during this study, we tend to aimed to see the security and effectuality of ixazomib as maintenance medical aid following ASCT.


The section three, double-blind, placebo-controlled TOURMALINE-MM3 study materialized in 167 clinical or hospital sites in thirty countries in Europe, the center East, Africa, Asia, and North and South America. Eligible participants were adults with a confirmed identification of symptomatic myeloma in step with International malignant neoplasm social unit criteria World Health Organization had achieved a minimum of a partial response once undergoing standard-of-care induction medical aid followed by high-dose cancer drug (200 mg/m2) acquisition and single ASCT among twelve months of diagnosis. Patients were arbitrarily appointed during a 3:2 quantitative relation to oral ixazomib or matching placebo on days one, 8, and fifteen in 28-day cycles for two years following induction, high-dose medical aid, and transplantation. The initial three mg dose was

increased to four mg from cycle five if tolerated throughout cycles 1–4. randomization was stratified by induction plan, pre-induction malady stage, and response post-transplantation. the first termination was progression-free survival (PFS) by intention-to-treat analysis. Safety was assessed altogether patients World Health Organization received a minimum of one dose of ixazomib or placebo, in step with treatment truly received. This trial is registered with, variety NCT02181413, and follow-up is in progress.


Between Gregorian calendar month thirty one, 2014, and March fourteen, 2016, 656 patients were listed and arbitrarily appointed to receive ixazomib maintenance medical aid (n=395) or placebo (n=261). With a median follow-up of thirty one months (IQR 27•3–35•7), we tend to determined a twenty eight reduction within the risk of progression or death with ixazomib versus placebo (median PFS 26•5 months [95% CI 23•7–33•8] vs 21•3 months [18•0–24•7]; hazard quantitative relation 0•72, ninety five CI 0•58–0•89; p=0•0023). No increase in second malignancies was noted with ixazomib medical aid (12 [3%] patients) compared with placebo (eight [3%] patients) at the time of this analysis. 108 (27%) of 394 patients within the ixazomib cluster and fifty one (20%) of 259 patients in the placebo group practised serious adverse events. throughout the treatment amount, one patient died within the ixazomib cluster and none died in the placebo group.


Ixazomib maintenance prolongs PFS and represents an extra choice for post-transplant maintenance medical aid in patients with freshly diagnosed myeloma.


Millennium prescription drugs, a completely in hand subsidiary of Takeda drug company. [2]

Everyone has a donor: contribution of the Chinese experience to global practice of haploidentical hematopoietic stem cell transplantation

Human free phagocyte matter (HLA)-matched donors for haemopoietic vegetative cell transplantation (HSCT) have long been scarce in China. Haploidentical (haplo) donors are on the market for the overwhelming majority of patients, however toxicity has restricted this approach. 3 new approaches for haplo-HSCT originated from Italian Republic, China, and USA in 1990 and are developed to world-renowned system up to currently. The Chinese approach are greatly improved by implementing new personalised learning regimens, donor choice supported non-HLA systems, risk-directed methods for graft-versus-host illness and relapse, and infection management. Haplo-HSCT has exhibited similar effectualness to HLA-matched HSCT and has step by step become the predominant donor supply and also the initial different donor alternative for allo-HSCT in China. Registry-based analyses and multicenter studies adhering to international standards expedited the transformation of the distinctive Chinese expertise into a plan for the refinement of world apply. This review can concentrate on however the new era during which “everyone includes a donor” will become a reality in China. [3]

Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation

Transplantation of hematogenic cells from a healthy individual (allogeneic hematopoietic cell transplantation (allo-HCT)) demonstrates that adoptive therapy will cure blood cancers: still, post-transplantation relapses stay frequent. to clarify their drivers, we have a tendency to analyzed the genomic and organic phenomenon profiles of acute chronic myelocytic leukemia (AML) blasts pure from patients at serial time-points throughout their sickness history. we have a tendency to known a transcriptional signature specific for post-transplantation relapses and extremely enriched in immune-related processes, as well as T lymphocyte costimulation and matter presentation. In 2 freelance patient cohorts we have a tendency to confirmed the liberation of multiple costimulatory ligands on AML blasts at post-transplantation relapse (PD-L1, B7-H3, CD80, PVRL2), reflected by concomitant changes in current donor T cells. Likewise, we have a tendency to documented the frequent loss of surface expression of HLA-DR, -DQ and -DP on leucaemia cells, thanks to downregulation of the HLA category II regulator CIITA. we have a tendency to show that loss of HLA category II expression and upregulation of restrictive stop molecules represent different modalities to get rid of AML recognition from donor-derived T cells, and might be counteracted by interferon-γ or stop blockade, severally. Our results demonstrate that the liberation of pathways concerned in T cell-mediated allorecognition could be a good taste and driver of AML relapses when allo-HCT, which might be chop-chop translated into personalised therapies. [4]

Clinicopathological Characteristics of Pernicious Anemia: A Study of 300 Patients in Turkey

Aims: Our study was undertaken to look at the laboratory and clinical options of pernicious anaemia patients presenting at first at the Turgut Ozal heart, that is a vital tertiary clinic in japanese Anatolia.

Study Design: Among patients evaluated for etiology of anemia, we tend to analysed the clinicopathological characteristics of three hundred (158 females and 142 males) patients with pernicious anaemia retrospectively.

Place and length of Study: Department of medicine and Division of medicine, Inonu University faculty of drugs, between 1996 and July 2011.

Methodology: descent counts, hormone levels, liver operate tests and LDH levels were reviewed for three hundred patients with pernicious anaemia retrospectively. Peripheral blood smears and bone marrow biopsies were reviewed by a haematologist. examination examination and ultrasonographic scrutiny were performed for symptom rubor, vesica stones and hepatosplenomegaly for all patients. Laboratory values, ages, signs and symptoms of patients at the time of designation were compared between genders.

Results: The mean age of the feminine patients was fifty.56 ± 17.75 years (17–84), whereas that of the male patients was fifty seven.24 ± 15.78 (20–95) years. At the time of designation, the male patients were older than the females (p = zero.002). LDH levels were considerably higher for females (p = zero.043). The incidence of gallstones was considerably higher in females (25.4%) than in males (10.7%) (p = 0,001). cytopenia was outlined as a haemoprotein level not up to ten gr/dl, leukocytes not up to one.500/µL and platelets not up to a hundred and fifty.000/µL and therefore the incidence of cytopenia was forty one.3% (n = 65) and fifty.7% (n = 71) within the feminine and male patients, severally, and therefore the distinction wasn’t statistically vital. There was no statistically vital distinction for frequency of thyroid sickness or symptoms and signs at the time of designation between genders.

Conclusions: pernicious anaemia isn’t a sickness of solely older women; it will be seen in each men and ladies of younger ages. it’s seen nearly as usually in ladies as in men. Gallstones and abnormal thyroid activity will be ascertained at these patients at the time of diagnosis; thus, these findings ought to be thought-about. [5]


[1] Marty, F.M., Winston, D.J., Chemaly, R.F., Mullane, K.M., Shore, T.B., Papanicolaou, G.A., Chittick, G., Brundage, T.M., Wilson, C., Morrison, M.E. and Foster, S.A., 2019. A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Oral Brincidofovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 25(2), pp.369-381. (Web Link)

[2] Dimopoulos, M.A., Gay, F., Schjesvold, F., Beksac, M., Hajek, R., Weisel, K.C., Goldschmidt, H., Maisnar, V., Moreau, P., Min, C.K. and Pluta, A., 2019. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. The Lancet, 393(10168), pp.253-264. (Web Link)

[3] Lv, M., Chang, Y. and Huang, X., 2019. Everyone has a donor: contribution of the Chinese experience to global practice of haploidentical hematopoietic stem cell transplantation. Frontiers of medicine, 13(1), pp.45-56. (Web Link)

[4] Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation

Cristina Toffalori, Laura Zito, […]Luca Vago

Nature Medicinevolume 25, pages603–611 (2019) (Web Link)

[5] Bentli, R., Berber, I., Erkurt, M., Aydogdu, I., Gunduz, E., Nizam, I., Kaya, E., Kuku, I. and Koroglu, M. (2013) “Clinicopathological Characteristics of Pernicious Anemia: A Study of 300 Patients in Turkey”, Journal of Advances in Medicine and Medical Research, 4(3), pp. 807-815. doi: 10.9734/BJMMR/2014/6147. (Web Link)